Lexicon Pharmaceuticals Inc
LXRX1.145USD
+0.075+7.01%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
415.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lexicon Pharmaceuticals Inc Unternehmen
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Unternehmensinformationen
BörsenkürzelLXRX
Name des UnternehmensLexicon Pharmaceuticals Inc
IPO-datumApr 07, 2000
CEOMr. Michael Exton
Anzahl der mitarbeiter103
WertpapierartOrdinary Share
GeschäftsjahresendeApr 07
Addresse2445 Technology Forest Blvd
StadtTHE WOODLANDS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl77381
Telefon12818633000
Websitehttps://www.lexpharma.com/
BörsenkürzelLXRX
IPO-datumApr 07, 2000
CEOMr. Michael Exton
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
Aktionäre
Aktionäre
Anteil
Artal International S.C.A.
37.50%
Invus Public Equities Advisors, LLC
10.72%
Fidelity Management & Research Company LLC
10.50%
The Vanguard Group, Inc.
2.63%
BlackRock Institutional Trust Company, N.A.
2.54%
Other
36.12%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
68.24%
Hedge Fund
3.93%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
1.23%
Research Firm
0.50%
Family Office
0.06%
Bank and Trust
0.05%
Pension Fund
0.01%
Other
22.25%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
320
282.21M
77.71%
-40.09M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
2023Q1
274
154.64M
82.03%
-4.81M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Artal International S.C.A.
136.18M
37.5%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
38.92M
10.72%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
34.54M
9.51%
-17.43M
-33.53%
Mar 31, 2025
The Vanguard Group, Inc.
9.56M
2.63%
-278.32K
-2.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.21M
2.54%
-237.79K
-2.52%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
8.21M
2.26%
+654.37K
+8.66%
Mar 31, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Geode Capital Management, L.L.C.
3.69M
1.02%
+168.02K
+4.77%
Mar 31, 2025
GSA Capital Partners LLP
807.49K
0.22%
+807.49K
--
Mar 31, 2025
State Street Global Advisors (US)
2.61M
0.72%
-110.67K
-4.07%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0%
Texas Capital Texas Equity Index ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.68%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0%
Texas Capital Texas Equity Index ETF
Anteil0%
Goldman Sachs Innovate Equity ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
